Shopping Cart
Remove All
Your shopping cart is currently empty
HI042 is an FMS-like tyrosine kinase 3 (FLT3) inhibitor, showing an IC50 value of 0.62 μM for MOLM-13 cells, 0.33 μM for MV4-11 cells, and 0.89 μM for OCI-AML3 cells. It selectively reduces the survival rate of FLT3-internal tandem duplication (FLT3-ITD) positive cell lines, induces apoptosis, disrupts cell cycle progression, and diminishes colony-forming ability. HI042 is applicable for acute myeloid leukemia (AML) research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | HI042 is an FMS-like tyrosine kinase 3 (FLT3) inhibitor, showing an IC50 value of 0.62 μM for MOLM-13 cells, 0.33 μM for MV4-11 cells, and 0.89 μM for OCI-AML3 cells. It selectively reduces the survival rate of FLT3-internal tandem duplication (FLT3-ITD) positive cell lines, induces apoptosis, disrupts cell cycle progression, and diminishes colony-forming ability. HI042 is applicable for acute myeloid leukemia (AML) research. |
| In vitro | HI042 exhibits different IC50 values for MOLM-13 cells at 24, 48, and 72 hours, measuring 0.88, 0.52, and 0.36 μM respectively, while for MV4-11 cells, the IC50 values are >40, 1.03, and 0.64 μM. HI042 concentrations ranging from 0.3-5 μM over 7-10 days reduce the autonomous colony growth of both MOLM-13 and MV4-11 cells. Additionally, at concentrations of 0.25-1 μM for 72 hours, HI042 can induce apoptosis and differentiation in these cells. When combined with Quizartinib (0.12-2 nM), HI042 (0.06-1 μM, 72 h) significantly decreases the activity of MOLM-13 and MV4-11 cells. |
| Molecular Weight | 301.32 |
| Formula | C14H11N3O3S |
| Cas No. | 898168-15-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.